A new trading day began on Thursday, with Cytokinetics Inc (NASDAQ: CYTK) stock price up 0.84% from the previous day of trading, before settling in for the closing price of $39.15. CYTK’s price has ranged from $32.74 to $69.90 over the past 52 weeks.
Here's Your FREE Report on the #1 Small-Cap Uranium Stock of '24.
Small-cap Uranium stocks are booming in 2024! The company we're about to show you is the ONLY small-cap stock in the space that benefits from ALL aspects of the global Uranium industry with none of the risks of running a mine. Smart investors will not be hesitating on this one!
Get the FREE Report with all the details here.
Sponsored
A company in the Healthcare sector has jumped its sales by 44.31% annually for the last half of the decade. Meanwhile, its annual earnings per share averaged -8.39%. With a float of $116.04 million, this company’s outstanding shares have now reached $118.21 million.
In an organization with 498 employees, it is important to assess its efficiency. In terms of profitability, gross margin is -890.46%, operating margin of -2902.72%, and the pretax margin is -3191.11%.
Cytokinetics Inc (CYTK) Insider Updates
As we move forward, let’s examine how large-scale investors are investing in this stock of the Biotechnology Industry. The insider ownership of Cytokinetics Inc is 2.62%, while institutional ownership is 109.38%. The most recent insider transaction that took place on Apr 15 ’25, was worth 123,325. In this transaction Director of this company sold 3,190 shares at a rate of $38.66, taking the stock ownership to the 66,348 shares. Before that another transaction happened on Apr 15 ’25, when Company’s Director proposed sale 3,190 for $39.81, making the entire transaction worth $126,994.
Cytokinetics Inc (CYTK) Performance Highlights and Predictions
Wall Street market experts anticipate that the next fiscal year will bring earnings of -1.4 per share during the current fiscal year.
According to the Wall Street analysts, stocks earnings will be around -8.39% per share during the next fiscal year. For the long-term projections, market analysts anticipate that the company’s EPS will surge by 18.86% during the next five years compared to -20.02% drop over the previous five years of trading.
Cytokinetics Inc (NASDAQ: CYTK) Trading Performance Indicators
Here are Cytokinetics Inc’s current performance indicators. According to the last quarter’s results, the stock had a quick ratio of 6.17. In addition, a publicly-traded company’s price to sales ratio for the trailing twelve months stands at 254.77.
For the trailing twelve months, Company’s Diluted EPS (Earnings per Share) is -5.28, a number that is poised to hit -1.37 in the next quarter and is forecasted to reach -4.78 in one year’s time.
Technical Analysis of Cytokinetics Inc (CYTK)
Let’s dig in a bit further. During the last 5-days, its volume was 2.25 million. That was better than the volume of 1.84 million it reported in year-ago period. As of the previous 9 days, the stock’s Stochastic %D was 77.30%. Additionally, its Average True Range was 2.81.
During the past 100 days, Cytokinetics Inc’s (CYTK) raw stochastic average was set at 33.53%, which indicates a significant decrease from 61.55% during the past two weeks. Based on volatility metrics of the stock, it showed a historical volatility of 76.68% in the past 14 days, which was higher than the 52.88% volatility it showed in the past 100 days.
At the time of writing, stock’s 50-day Moving Average is $42.94, while its 200-day Moving Average is $50.45. However, in the short run, Cytokinetics Inc’s stock first resistance to watch stands at $39.87. Second resistance stands at $40.26. The third major resistance level sits at $40.99. If the price goes on to break the first support level at $38.75, it is likely to go to the next support level at $38.02. Assuming the price breaks the second support level, the third support level stands at $37.63.
Cytokinetics Inc (NASDAQ: CYTK) Key Stats
With a market capitalization of 4.71 billion, the company has a total of 119,188K Shares Outstanding. Currently, annual sales are 18,470 K while annual income is -589,530 K. The company’s previous quarter sales were 16,930 K while its latest quarter income was -150,020 K.
